BioMarin lands 20% Yuviwel royalty in Ascendis patent settlement

BioMarin secured a patent settlement with Ascendis Pharma granting BioMarin a 20% royalty on Yuviwel net sales in the US and 18% in the EU, Brazil, and South Korea through May 2030. This resolves ongoing patent disputes and provides BioMarin with a royalty stream from a competitor's commercially launched drug in the rare disease achondroplasia market.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 31 Aug 2026 and 1 Sep 2026.